Charles River Laboratorie... (CRL)
Charles River Laboratories International Inc. (CRL) Stock Price, Analysis & Data
| Bid | n/a |
| Market Cap | 13.81B |
| Revenue (ttm) | 4B |
| Net Income (ttm) | -238.46M |
| Beta | 1.38 |
| EPS (ttm) | -4.93 |
| PE Ratio (ttm) | n/a |
| Forward PE | 22.59 |
| P/B (ttm) | 4.82 |
| P/S (ttm) | 3.42 |
| Earnings Date | Nov 4, 2026 |
| Ask | 302.6 |
| Volume | 856,790 |
| Avg. Volume (20D) | 901,595 |
| Open | 279.48 |
| Previous Close | 280.05 |
| Day's Range | 279.37 - 288.88 |
| 52-Week Range | 144.26 - 288.88 |
| Analyst | Buy |
| Price Target | 300 (4.66%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CRL
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research a...
Financial Performance
In 2025, Charles River Laboratories International's revenue was 4.02B, a decrease of -0.85% compared to the previous year's 4.05B. Earnings were -144.34M, a decrease of -1,501.75%.
Financial StatementsAnalyst Forecast
According to 14 analyst ratings, the average rating for CRL stock is "Buy". The 12-month stock price forecast is 300, which is upside of 4.66% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
